HU229997B1 - Peptides as ns3-serine protease inhibitors of hepatitis c virus - Google Patents

Peptides as ns3-serine protease inhibitors of hepatitis c virus

Info

Publication number
HU229997B1
HU229997B1 HU0401730A HUP0401730A HU229997B1 HU 229997 B1 HU229997 B1 HU 229997B1 HU 0401730 A HU0401730 A HU 0401730A HU P0401730 A HUP0401730 A HU P0401730A HU 229997 B1 HU229997 B1 HU 229997B1
Authority
HU
Hungary
Prior art keywords
hepatitis
peptides
virus
protease inhibitors
serine protease
Prior art date
Application number
HU0401730A
Other languages
English (en)
Hungarian (hu)
Inventor
Anil K Saksena
Viyyoor Moopil Parsippany Girijavallabhan
Raymond G Lovey
Edwin E Jao
Frank Bennett
Jinping Mccormick
Haiyan Wang
Russel E Pike
Stephane L Bogen
Tin-Yau Chan
Yi-Tsung Liu
Zhaoning Zhu
F George Njoroge
Ashok Arasappan
Tejal N Parekh
Ashit K Ganguly
Kevin X Chen
Srikanth Venkatraman
Henry A Vaccaro
Patrick A Pinto
Bama Santhanam
Wanli Wu
Siska Hendrata
Yuhua Huang
Scott Kemp
Odile Esther Levy
Marguerita Lim-Wilby
Susan Y Tamura
Original Assignee
Dendreon Corp San Diego
Merck Sharp & Dohme Corp Rahway
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22822095&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HU229997(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Dendreon Corp San Diego, Merck Sharp & Dohme Corp Rahway filed Critical Dendreon Corp San Diego
Publication of HUP0401730A2 publication Critical patent/HUP0401730A2/hu
Publication of HUP0401730A3 publication Critical patent/HUP0401730A3/hu
Publication of HU229997B1 publication Critical patent/HU229997B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HU0401730A 2000-07-21 2001-07-19 Peptides as ns3-serine protease inhibitors of hepatitis c virus HU229997B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22010800P 2000-07-21 2000-07-21
PCT/US2001/022678 WO2002008244A2 (en) 2000-07-21 2001-07-19 Peptides as ns3-serine protease inhibitors of hepatitis c virus

Publications (3)

Publication Number Publication Date
HUP0401730A2 HUP0401730A2 (hu) 2004-12-28
HUP0401730A3 HUP0401730A3 (en) 2012-09-28
HU229997B1 true HU229997B1 (en) 2015-04-28

Family

ID=22822095

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0401730A HU229997B1 (en) 2000-07-21 2001-07-19 Peptides as ns3-serine protease inhibitors of hepatitis c virus

Country Status (31)

Country Link
US (4) US7012066B2 (enExample)
EP (1) EP1385870B1 (enExample)
JP (3) JP4298289B2 (enExample)
KR (2) KR100939155B1 (enExample)
CN (3) CN102372764A (enExample)
AR (2) AR033985A1 (enExample)
AT (1) ATE461207T1 (enExample)
AU (2) AU7698801A (enExample)
BR (1) BR0112540A (enExample)
CA (1) CA2410662C (enExample)
CY (2) CY1112267T1 (enExample)
CZ (1) CZ303213B6 (enExample)
DE (2) DE60141608D1 (enExample)
DK (1) DK1385870T3 (enExample)
EC (1) ECSP034438A (enExample)
ES (1) ES2341534T3 (enExample)
HU (1) HU229997B1 (enExample)
IL (2) IL153670A0 (enExample)
LU (1) LU91910I2 (enExample)
MX (1) MXPA03000627A (enExample)
MY (2) MY139078A (enExample)
NO (2) NO332329B1 (enExample)
NZ (1) NZ523782A (enExample)
PL (1) PL206255B1 (enExample)
PT (1) PT1385870E (enExample)
RU (2) RU2355700C9 (enExample)
SI (1) SI1385870T1 (enExample)
SK (1) SK288064B6 (enExample)
TW (1) TWI324611B (enExample)
WO (1) WO2002008244A2 (enExample)
ZA (1) ZA200210312B (enExample)

Families Citing this family (276)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298749B6 (cs) 1996-10-18 2008-01-16 Vertex Pharmaceuticals Incorporated Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
PE20011350A1 (es) 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
MXPA03000627A (es) * 2000-07-21 2004-07-30 Schering Corp Nuevos peptidos como inhibidores de proteasa serina-ns3 del virus de la hepatitis c.
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
SV2003000617A (es) * 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
ES2266258T3 (es) 2000-09-15 2007-03-01 Vertex Pharmaceuticals Incorporated Compuestos de pirazol utiles como inhibidores de proteina cinasas.
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
GB2367816A (en) * 2000-10-09 2002-04-17 Bayer Ag Urea- and thiourea-containing derivatives of beta-amino acids
HUP0303436A2 (hu) * 2000-12-12 2004-01-28 Schering Corp. Diaril-peptidek mint a hepatitis C vírus NS3-szerin proteáz inhibitorai, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
EP1345925B1 (en) 2000-12-21 2006-05-17 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
CA2449504A1 (en) 2001-07-11 2003-01-23 Vertex Pharmaceuticals Incorporated Bridged bicyclic serine protease inhibitors
NZ531681A (en) 2001-10-24 2007-05-31 Vertex Pharma Inhibitors of serine protease, particularly hepatitis C virus NS3-NS4A protease, incorporating a fused ring system
AU2003207625B2 (en) * 2002-01-23 2006-09-07 Schering Corporation Proline compounds as NS3-serine protease inhibitors for use in treatment of hepatites C virus infection
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
JP2005535574A (ja) 2002-04-11 2005-11-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド セリンプロテアーゼ、特にｈｃｖｎｓ３−ｎｓ４ａプロテアーゼのインヒビター
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
AU2011203054B2 (en) * 2003-04-11 2012-04-26 Vertex Pharmaceuticals, Incorporated Inhibitors of Serine Proteases, Particularly HCV NS3-NS4A Protease
ATE547412T1 (de) 2003-04-11 2012-03-15 Vertex Pharma Inhibitoren von serinproteasen, insbesondere hcv- ns3-ns4a-protease
HRP20080014T3 (en) 2003-05-21 2008-02-29 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
EP1633698A1 (en) * 2003-06-17 2006-03-15 Schering Corporation Process and intermediates for the preparation of 3-(amino)-3-cyclobutylmethyl-2-hydroxy-propionamide or salts thereof
AR044694A1 (es) * 2003-06-17 2005-09-21 Schering Corp Proceso y compuestos intermedios para la preparacion de (1r, 2s,5s) - 3 azabiciclo [3,1,0] hexano-2- carboxamida, n- [3- amino-1- (ciclobutilmetil) - 2, 3 - dioxopropil] -3- [ (2s) - 2 - [[ [ 1,1- dimetiletil] amino] carbonilamino] -3,3-dimetil -1- oxobutil]-6,6 dimetilo
MXPA05013752A (es) * 2003-06-17 2006-03-08 Schering Corp Procedimiento e intermediarios para la preparacion de (1r,2s,5s)-6,6-dimetil-3-azabiciclo[3,1,0]exan-2-carboxilatos o sales de los mismos.
BRPI0412761A (pt) 2003-07-18 2006-09-26 Vertex Pharma inibidores de serino proteases, particularmente a protease ns3-ns4a do vhc
WO2005021584A2 (en) * 2003-08-26 2005-03-10 Schering Corporation Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus
PE20050374A1 (es) 2003-09-05 2005-05-30 Vertex Pharma Inhibidores de proteasas de serina, en particular proteasa ns3-ns4a del vhc
CA2538791A1 (en) * 2003-09-18 2005-03-31 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
RS20060197A (sr) 2003-09-22 2008-09-29 Boehringer Ingelheim International Gmbh., Makrociklični peptidi koji su aktivni protiv hepatitisa c virusa
KR20060085248A (ko) * 2003-09-26 2006-07-26 쉐링 코포레이션 Ｃ형 간염 바이러스 ｎｓ3 세린 프로테아제의마크로사이클릭 억제제
CA2541634A1 (en) * 2003-10-10 2005-04-28 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly hcv ns3-ns4a protease
US7491794B2 (en) * 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
JP4890254B2 (ja) 2003-10-27 2012-03-07 バーテックス ファーマシューティカルズ インコーポレイテッド Ｈｃｖｎｓ３−ｎｓ４ａプロテアーゼ耐性突然変異体
EP1944042A1 (en) 2003-10-27 2008-07-16 Vertex Pharmceuticals Incorporated Combinations for HCV treatment
US8187874B2 (en) 2003-10-27 2012-05-29 Vertex Pharmaceuticals Incorporated Drug discovery method
JP2007532479A (ja) 2003-11-20 2007-11-15 シェーリング　コーポレイション Ｃ型肝炎ウイルスｎｓ３プロテアーゼの脱ペプチド化インヒビター
CA2549167A1 (en) * 2003-12-11 2005-06-30 Schering Corporation Inhibitors of hepatitis c virus ns3/ns4a serine protease
ATE495185T1 (de) 2004-01-21 2011-01-15 Boehringer Ingelheim Int Makrocyclische peptide mit wirkung gegen das hepatitis-c-virus
KR20120090077A (ko) * 2004-01-30 2012-08-16 얀센 알 앤드 디 아일랜드 Ｈｃｖ ｎｓ?３ 세린 프로테아제 저해제
EP2311851A3 (en) 2004-02-04 2011-05-25 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
PT1719773E (pt) 2004-02-24 2009-06-03 Japan Tobacco Inc Compostos heterotetracíclicos fundidos e a sua utilização como inibidores da polimerase do hcv
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
US7192957B2 (en) * 2004-02-27 2007-03-20 Schering Corporation Compounds as inhibitors of hepatitis C virus NS3 serine protease
DE602005023224D1 (de) * 2004-02-27 2010-10-07 Schering Corp Neuartige Verbindungen als Hemmer von Hepatitis C-Virus NS3-Serinprotease
US7635694B2 (en) 2004-02-27 2009-12-22 Schering Corporation Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease
US7205330B2 (en) * 2004-02-27 2007-04-17 Schering Corporation Inhibitors of hepatitis C virus NS3 protease
AU2005219824B2 (en) * 2004-02-27 2007-11-29 Merck Sharp & Dohme Corp. Novel ketoamides with cyclic p4's as inhibitors of ns3 serine protease of hepatitis c virus
MY145081A (en) * 2004-02-27 2011-12-15 Schering Corp Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
CN1946690A (zh) * 2004-02-27 2007-04-11 先灵公司 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的含环丁烯二酮基团化合物
US7816326B2 (en) * 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
ES2328589T3 (es) * 2004-02-27 2009-11-16 Schering Corporation Compuestos de la prolina 3,4(ciclopentil) fusionados como inhibidores de la proteasa serina ns3 del virus de la hepatitis c.
KR101135765B1 (ko) * 2004-03-12 2012-04-23 버텍스 파마슈티칼스 인코포레이티드 아스파르트산 아세탈 카스파아제 억제제의 제조를 위한방법 및 중간체
AR049635A1 (es) * 2004-05-06 2006-08-23 Schering Corp (1r,2s,5s)-n-((1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil)-3-((2s)-2-((((1,1-dimetiletil)amino)carbonil)amino)-3,3-dimetil-1-oxobutil)-6,6-dimetil-3-azabiciclo(3.1.0)hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de la hepatitis c
CN1984922A (zh) 2004-05-20 2007-06-20 先灵公司 用作丙型肝炎病毒ns3丝氨酸蛋白酶抑制剂的取代脯氨酸
JP4914355B2 (ja) 2004-07-20 2012-04-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃ型肝炎インヒビターペプチド類似体
UY29016A1 (es) 2004-07-20 2006-02-24 Boehringer Ingelheim Int Analogos de dipeptidos inhibidores de la hepatitis c
CA2577812A1 (en) 2004-08-27 2006-03-09 Schering Corporation Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease
US7196161B2 (en) * 2004-10-01 2007-03-27 Scynexis Inc. 3-ether and 3-thioether substituted cyclosporin derivatives for the treatment and prevention of hepatitis C infection
CA2583472A1 (en) 2004-10-01 2006-04-13 Chao Lin Hcv ns3-ns4a protease inhibition
JP5139065B2 (ja) * 2004-10-01 2013-02-06 スシネキス インク Ｃ型肝炎感染の治療及び予防のための３−エーテル及び３−チオエーテル置換シクロスポリン誘導体
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
GB0426661D0 (en) * 2004-12-06 2005-01-05 Isis Innovation Pyrrolidine compounds
WO2006130554A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis c virus
US20060276406A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
US20060281689A1 (en) * 2005-06-02 2006-12-14 Schering Corporation Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
WO2006130627A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods for treating hepatitis c
WO2006130686A2 (en) 2005-06-02 2006-12-07 Schering Corporation Hcv protease inhibitors in combination with food
US20060275366A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
WO2006130687A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor
CN101212970B (zh) 2005-06-02 2010-07-21 先灵公司 Hcv蛋白酶抑制剂与表面活性剂的组合物
NZ563369A (en) * 2005-06-02 2011-03-31 Schering Corp Controlled-release formulation useful for treating disorders associated with hepatitus C virus
ZA200711069B (en) * 2005-06-30 2009-03-25 Virobay Inc HCV inhibitors
US7608592B2 (en) * 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
US20110104109A1 (en) * 2005-07-13 2011-05-05 Frank Bennett Tetracyclic indole derivatives and their use for treating or preventing viral infections
JP5249028B2 (ja) 2005-07-25 2013-07-31 インターミューン・インコーポレーテッド Ｃ型肝炎ウイルス複製の新規大環状阻害剤
ES2373685T3 (es) 2005-07-29 2012-02-07 Tibotec Pharmaceuticals Inhibidores macrocíclicos del virus de la hepatitis c.
TWI412535B (zh) 2005-07-29 2013-10-21 Tibotec Pharm Ltd Ｃ型肝炎病毒之大環抑制劑（五）
CA2617679A1 (en) * 2005-08-02 2007-02-08 Steve Lyons Inhibitors of serine proteases
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
CA2619659A1 (en) 2005-08-19 2007-02-22 Vertex Pharmaceuticals Incorporated Processes and intermediates
AR055395A1 (es) * 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7964624B1 (en) * 2005-08-26 2011-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
BRPI0616476A2 (pt) * 2005-09-30 2011-06-21 Scynexis Inc uso de uma quantidade terapeuticamente eficaz de um derivado de ciclosporina, e, composição farmacêutica
US8329658B2 (en) * 2005-09-30 2012-12-11 Scynexis, Inc. Arylalkyl and heteroarylalkyl derivatives of cyclosporine A for the treatment and prevention of viral infection
GEP20104956B (en) * 2005-10-11 2010-04-12 Array Biopharma Inc Compounds for inhibiting hepatitis c viral replication and use thereof
WO2007056163A2 (en) 2005-11-03 2007-05-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
AU2006315438A1 (en) 2005-11-11 2007-05-24 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
US7705138B2 (en) 2005-11-11 2010-04-27 Vertex Pharmaceuticals Incorporated Hepatitis C virus variants
AR056805A1 (es) * 2005-11-14 2007-10-24 Schering Corp Un proceso para oxidacion para la preparcion de n- (3- amino-1- ( ciclobutilmetil) -2,3- dioxopropil ) -3-(n-(( ter-butilamino) carbonil )-3- metil- l- valil) -6,6- dimetil-3- azabiciclo (3.1.0) hexano -2- carboxamida y compuestos ralacionados
EP1963267B1 (en) * 2005-12-22 2013-08-14 Merck Sharp & Dohme Corp. Process for the preparation of 6, 6-dimethyl-3-azabicyclo-[3.1.0]-hexane compounds and enantiomeric salts thereof
DK1966130T3 (da) 2005-12-23 2014-02-10 Zealand Pharma As Modificerede lysin-mimetiske forbindelser
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
AR059430A1 (es) * 2006-02-09 2008-04-09 Schering Corp Novedosas combinaciones y metodos de inhibidores del vhc
US20070274951A1 (en) * 2006-02-09 2007-11-29 Xiao Tong Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto
CA2643688A1 (en) * 2006-02-27 2007-08-30 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
MX2008011354A (es) * 2006-03-03 2008-09-15 Schering Corp Combinaciones farmaceuticas de inhibidores de proteasa del virus de hepatitis c y del sitio interno de entrada ribosomal del virus de hepatitis c.
CA2645684A1 (en) * 2006-03-06 2007-09-13 Abbott Laboratories Compositions and methods of use of ritonavir for treating hcv
WO2007109080A2 (en) 2006-03-16 2007-09-27 Vertex Pharmaceuticals Incorporated Deuterated hepatitis c protease inhibitors
US20080045530A1 (en) * 2006-04-11 2008-02-21 Trixi Brandl Organic Compounds and Their Uses
CA2643680A1 (en) * 2006-04-11 2007-11-22 Novartis Ag Hcv/hiv inhibitors and their uses
MX2008013125A (es) * 2006-04-11 2008-10-21 Novartis Ag Compuestos organicos y sus usos.
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
CN101495095B (zh) * 2006-04-28 2013-05-29 默沙东公司 通过受控的沉淀来沉淀和分离6,6-二甲基-3-氮杂-双环[3.1.0]己烷-酰胺化合物的方法和含有其的药学制剂
EP2012753A2 (en) * 2006-04-28 2009-01-14 Schering Corporation Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0]hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
US8420122B2 (en) * 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
ATE502633T1 (de) 2006-05-19 2011-04-15 Scynexis Inc Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
RU2419625C2 (ru) * 2006-05-23 2011-05-27 Айрм Ллк Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы
US7951823B2 (en) * 2006-05-23 2011-05-31 Irm Llc Compounds and compositions as channel activating protease inhibitors
EP2027761A1 (fr) * 2006-06-02 2009-02-25 Claude Annie Perrichon Gestion des electrons actifs
KR20090024834A (ko) * 2006-07-05 2009-03-09 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 억제제
EP2049474B1 (en) 2006-07-11 2015-11-04 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
JP2010500978A (ja) 2006-08-17 2010-01-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ウイルスポリメラーゼインヒビター
US20080182895A1 (en) * 2006-08-25 2008-07-31 Howe Anita Y M Identification and characterization of hcv replicon variants with reduced susceptibility to hcv-796, and methods related thereto
US20100204159A1 (en) * 2006-09-13 2010-08-12 Trixl Brandl Organic compounds and their uses
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7576057B2 (en) 2006-11-20 2009-08-18 Scynexis, Inc. Cyclic peptides
JP2010510246A (ja) * 2006-11-21 2010-04-02 スミスクライン ビーチャム コーポレーション アミド抗ウイルス化合物
US20100055071A1 (en) * 2006-11-21 2010-03-04 Martin Robert Leivers Anti-Viral Compounds
WO2008073282A2 (en) * 2006-12-07 2008-06-19 Schering Corporation Ph sensitive matrix formulation
CA2672268A1 (en) * 2006-12-15 2008-06-26 Schering Corporation Bisulfite purification of an alpha-keto amide
PL2121605T3 (pl) * 2006-12-20 2014-05-30 Merck Sharp & Dohme Sposób otrzymywania (1R,2S,5S)-N-[(1S)-3-amino-1-(cyklobutylo-metylo)-2,3-dioksypropylo]-3-[(2S)-2-[[[(1,1-dimetyloetylo)amino]-karbonylo]amino]-3,3-dimetylo-1-oksybutylo]-6,6-dimetylo-3-azabicyklo[3.1.0]heksano-2-karboksyamidu
WO2008079266A2 (en) 2006-12-21 2008-07-03 Wyeth Synthesis of pyrrolidine compounds
CA2674831A1 (en) 2006-12-22 2008-11-13 Schering Corporation 5,6-ring annulated indole derivatives and methods of use thereof
MX2009006880A (es) 2006-12-22 2009-07-03 Schering Corp Derivados indolicos con anillo unido en las posiciones 4,5 para tratar o prevenir infecciones virales por virus de la hepatitis c e infecciones virales relacionadas.
JP5211068B2 (ja) * 2006-12-22 2013-06-12 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖおよび関連するウイルス疾患の治療または予防のための４，５−環インドール誘導体
US20080161254A1 (en) * 2007-01-03 2008-07-03 Virobay, Inc. Hcv inhibitors
KR20090108131A (ko) * 2007-02-09 2009-10-14 아이알엠 엘엘씨 채널 활성화 프로테아제 억제제로서의 화합물 및 조성물
WO2008106058A2 (en) * 2007-02-27 2008-09-04 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases
GEP20125645B (en) * 2007-02-27 2012-09-25 Vertex Pharma Co-crystals and pharmaceutical compositions comprising the same
JP2010522172A (ja) * 2007-03-23 2010-07-01 シェーリング コーポレイション Ｈｃｖｎｓ３プロテアーゼのｐ１−非エピメリ化ケトアミド阻害剤
KR20100024920A (ko) * 2007-05-03 2010-03-08 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규 마크로사이클릭 저해제
ES2381410T3 (es) 2007-05-04 2012-05-28 Vertex Pharmceuticals Incorporated Terapia de combinación paa el tratamiento de infecciones por VHC
MX2009012093A (es) * 2007-05-10 2010-01-25 Intermune Inc Nuevos peptidos inhibidores de la replicacion del virus de la hepatitis c.
EP2188274A4 (en) 2007-08-03 2011-05-25 Boehringer Ingelheim Int VIRAL POLYMERASE HEMMER
CA2697500A1 (en) 2007-08-29 2009-03-12 Schering Corporation 2,3-substituted azaindole derivatives for treating viral infections
ES2447543T3 (es) * 2007-08-29 2014-03-12 Merck Sharp & Dohme Corp. Derivados de indol sustituidos y métodos de utilización de los mismos
EP2197842B1 (en) * 2007-08-29 2012-05-23 Schering Corporation 2, 3-substituted indole derivatives for treating viral infections
WO2009032198A1 (en) 2007-08-30 2009-03-12 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical compositions comprising the same
AU2008301981A1 (en) * 2007-09-14 2009-03-26 Merck Sharp & Dohme Corp. Method of treating hepatitis C patients
BRPI0817881A2 (pt) * 2007-10-10 2015-03-31 Novartis Ag Compostos orgânicos e seus usos
US8419332B2 (en) * 2007-10-19 2013-04-16 Atlas Bolt & Screw Company Llc Non-dimpling fastener
EP2222672B1 (en) * 2007-11-16 2013-12-18 Merck Sharp & Dohme Corp. 3-aminosulfonyl substituted indole derivatives and methods of use thereof
CA2705586A1 (en) * 2007-11-16 2009-05-22 Schering Corporation 3-heterocyclic substituted indole derivatives and methods of use thereof
CN101910130A (zh) * 2007-11-28 2010-12-08 先灵公司 制备用于形成6,6-二甲基-3-氮杂双环[3.1.0]己烷化合物的中间体的脱卤化氢方法
WO2009076747A1 (en) 2007-12-19 2009-06-25 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
CN102089274B (zh) * 2007-12-21 2014-09-10 默沙东公司 合成3-氨基-3-环丁基甲基-2-羟基丙酰胺或其盐的方法
KR20100118991A (ko) 2008-02-04 2010-11-08 아이데닉스 파마슈티칼스, 인코포레이티드 매크로시클릭 세린 프로테아제 억제제
KR20110005869A (ko) * 2008-04-15 2011-01-19 인터뮨, 인크. Ｃ형 간염 바이러스 복제의 신규한 마크로사이클릭 억제제
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044023B2 (en) 2008-05-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9090671B2 (en) * 2008-06-06 2015-07-28 Scynexis, Inc. Macrocyclic peptides
US20090306033A1 (en) * 2008-06-06 2009-12-10 Keqiang Li Novel cyclic peptides
WO2009152200A1 (en) * 2008-06-13 2009-12-17 Schering Corporation Tricyclic indole derivatives and methods of use thereof
CA2728226A1 (en) 2008-06-24 2010-01-21 Codexis, Inc. Biocatalytic processes for the preparation of substantially stereomerically pure fused bicyclic proline compounds
US8188137B2 (en) 2008-08-15 2012-05-29 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
TW201020245A (en) 2008-08-20 2010-06-01 Schering Corp Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
WO2010022126A1 (en) 2008-08-20 2010-02-25 Schering Corporation Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2734486A1 (en) 2008-08-20 2010-02-25 Southern Research Institute Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
ES2439009T3 (es) 2008-08-20 2014-01-21 Merck Sharp & Dohme Corp. Derivados de piridina y pirimidina sustituidos con etenilo y su uso en el tratamiento de infecciones virales
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102216321A (zh) * 2008-10-15 2011-10-12 因特蒙公司 治疗性抗病毒肽
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2376524B1 (en) * 2008-12-31 2017-03-15 Cypralis Limited Derivatives of cyclosporin a
WO2010080874A1 (en) 2009-01-07 2010-07-15 Scynexis, Inc. Cyclosporine derivative for use in the treatment of hcv and hiv infection
GB0900914D0 (en) 2009-01-20 2009-03-04 Angeletti P Ist Richerche Bio Antiviral agents
US8102720B2 (en) * 2009-02-02 2012-01-24 Qualcomm Incorporated System and method of pulse generation
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
JP5690286B2 (ja) 2009-03-04 2015-03-25 イデニク プハルマセウティカルス，インコーポレイテッド ホスホチオフェン及びホスホチアゾールｈｃｖポリメラーゼ阻害剤
US8377962B2 (en) 2009-04-08 2013-02-19 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US20110182850A1 (en) * 2009-04-10 2011-07-28 Trixi Brandl Organic compounds and their uses
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
US20120244122A1 (en) 2009-05-28 2012-09-27 Masse Craig E Peptides for the Treatment of HCV Infections
CA2763140A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
WO2010151488A1 (en) 2009-06-23 2010-12-29 Gilead Sciences, Inc. Combination of boceprevir with 5- ( { 6- [2, 4- bis (trifluoromethyl) phenyl] pyridazin-3 -yl } methyl) -2- (2 -fluorophenyl) -5h- imidazo [4, 5-c] pyridine for the treatment of hcv
AR077688A1 (es) 2009-08-04 2011-09-14 Takeda Pharmaceutical Compuestos heterociclicos, utiles en el tratamiento de cancer
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
US9156818B2 (en) 2009-09-11 2015-10-13 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011038293A1 (en) * 2009-09-28 2011-03-31 Intermune, Inc. Cyclic peptide inhibitors of hepatitis c virus replication
WO2011041551A1 (en) * 2009-10-01 2011-04-07 Intermune, Inc. Therapeutic antiviral peptides
US20110117055A1 (en) 2009-11-19 2011-05-19 Macdonald James E Methods of Treating Hepatitis C Virus with Oxoacetamide Compounds
AU2010324871A1 (en) 2009-11-25 2012-06-14 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
SG181797A1 (en) 2009-12-18 2012-07-30 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
CA2785488A1 (en) 2009-12-22 2011-07-21 Merck Sharp & Dohme Corp. Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
US9433621B2 (en) 2010-02-18 2016-09-06 Merck Sharp & Dohme Corp. Substituted pyridine and pyrimidine derivatives and their use in treating viral infections
CA2791045A1 (en) * 2010-02-25 2011-09-01 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patieentenzorg A process for the preparation of substituted prolyl peptides and similar peptidomimetics
EP2545060B1 (en) 2010-03-09 2015-11-25 Merck Sharp & Dohme Corp. Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
WO2012018534A2 (en) 2010-07-26 2012-02-09 Schering Corporation Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
EP2621279B1 (en) 2010-09-29 2018-04-04 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
EP2696681B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013039876A1 (en) 2011-09-14 2013-03-21 Merck Sharp & Dohme Corp. Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
CA2811203C (en) 2011-10-21 2015-05-05 Abbvie Inc. Methods for treating hcv
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US20130123325A1 (en) 2011-11-14 2013-05-16 Sven Ruf Use of boceprevir and related compounds in atherosclerosis, heart failure, renal diseases, liver diseases or inflammatory diseases
AR091192A1 (es) * 2012-05-30 2015-01-21 Chemo Iberica Sa Procedimiento multicomponente para la preparacion de compuestos biciclicos
CN103508918B (zh) * 2012-06-18 2015-09-09 上海医药工业研究院 带有环丁基的α-羟基β-氨基酯类化合物及其制备方法
WO2014053533A1 (en) 2012-10-05 2014-04-10 Sanofi Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation
WO2014061034A1 (en) * 2012-10-18 2014-04-24 Msn Laboratories Limited Process for preparation of boceprevir and intermediates thereof
SI2909205T1 (sl) 2012-10-19 2017-02-28 Bristol-Myers Squibb Company 9-metil substituiran heksadekahidrociklopropa(e)pirolo(1,2-A)(1,4)diazaciklopentadecinil karbamat derivati kot nestrukturalni 3 (NS3) proteazni inhibitorji za zdravljenje hepatitis C virusnih infekcij
WO2014068265A1 (en) 2012-10-29 2014-05-08 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2914598B1 (en) 2012-11-02 2017-10-18 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014083575A2 (en) 2012-11-29 2014-06-05 Mylan Laboratories Ltd Improved process for the preparation of boceprevir intermediate
CN103936652B (zh) * 2013-01-18 2016-07-06 上海医药工业研究院 抗丙肝药物Boceprevir的中间体IV及其制备方法和应用
CN103936818B (zh) * 2013-01-18 2017-09-29 上海医药工业研究院 抗丙肝药物Boceprevir的中间体Ⅰ及其制备方法和应用
CN103936627B (zh) * 2013-01-18 2016-08-31 上海医药工业研究院 抗丙肝药物Boceprevir的中间体Ⅶ及其制备方法和应用
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
EA030957B1 (ru) 2013-03-14 2018-10-31 Оникс Терапьютикс, Инк. Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы
EP3184095A1 (en) 2013-05-23 2017-06-28 IP Gesellschaft für Management mbH Administration units comprising polymorph 1 of 2-(2-methylamino-pyrimidin-4-yl]-1h-indole-5-carboxylic acid [(s)-1-carbamoyl-2-(phenyl-pyrimidin-2-yl-amino)-ethyl]-amide
CN103387510B (zh) * 2013-08-08 2015-09-09 苏州永健生物医药有限公司 一种β-氨基-alpha-羟基环丁基丁酰胺盐酸盐的合成方法
WO2015042375A1 (en) 2013-09-20 2015-03-26 Idenix Pharmaceuticals, Inc. Hepatitis c virus inhibitors
EP3060554A1 (en) * 2013-10-24 2016-08-31 Bristol-Myers Squibb Company Inhibitors of human immunodeficiency virus replication
US10167298B2 (en) 2013-10-30 2019-01-01 Merck Sharp & Dohme Corp. Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof
EP2899207A1 (en) 2014-01-28 2015-07-29 Amikana.Biologics New method for testing HCV protease inhibition
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
WO2015134561A1 (en) 2014-03-05 2015-09-11 Idenix Pharmaceuticals, Inc. Pharmaceutical compositions comprising a 5,5-fused heteroarylene flaviviridae inhibitor and their use for treating or preventing flaviviridae infection
CN106810485A (zh) * 2015-11-27 2017-06-09 上海现代制药股份有限公司 一种手性联苯吡咯烷酮的制备方法及其中间体
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
EP4257191A3 (en) * 2016-06-21 2023-11-22 Orion Ophthalmology LLC Heterocyclic prolinamide derivatives
JP7076438B2 (ja) * 2016-06-21 2022-05-27 オリオン・オフサルモロジー・エルエルシー 脂肪族プロリンアミド誘導体
WO2017222914A1 (en) 2016-06-21 2017-12-28 Inception 4, Inc. Carbocyclic prolinamide derivatives
WO2018073110A1 (en) 2016-10-20 2018-04-26 Basf Se Quinoline compounds as fungicides
WO2018134127A1 (en) 2017-01-23 2018-07-26 Basf Se Fungicidal pyridine compounds
US20200187500A1 (en) 2017-04-06 2020-06-18 Basf Se Pyridine compounds
JP6989864B2 (ja) 2017-05-05 2022-02-03 ジーランド ファーマ，アー／エス ギャップ結合細胞間コミュニケーションモジュレータ及び糖尿病性眼疾患の治療のためのそれらの使用
US20220106308A1 (en) 2019-02-19 2022-04-07 Univerza V Ljubljani Antibacterials based on monocyclic fragments coupled to aminopiperidine naphthyridine scaffold
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
WO2022013684A1 (en) 2020-07-11 2022-01-20 Pfizer Inc. Antiviral heteroaryl ketone derivatives
SMT202500351T1 (it) * 2020-07-20 2025-11-10 Enanta Pharm Inc Peptidi funzionalizzati contenenti due anelli di pirrolidina come agenti anti-coronavirus
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
KR20230124583A (ko) 2020-11-23 2023-08-25 이난타 파마슈티칼스, 인코포레이티드 신규한 스피로피롤리딘 유래 항바이러스제
US12540141B2 (en) 2020-11-23 2026-02-03 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US20240217930A1 (en) * 2021-04-01 2024-07-04 Heptares Therapeutics Limited Sars-cov-2 mpro inhibitor compounds
RS66213B1 (sr) * 2021-04-16 2024-12-31 Fujian Akeylink Biotechnology Co Ltd Jedinjenje kratkog peptida prolina modifikovanog prstenom i upotreba istog
WO2022235605A1 (en) 2021-05-04 2022-11-10 Enanta Pharmaceuticals, Inc. Novel macrocyclic antiviral agents
US12398147B2 (en) 2021-05-11 2025-08-26 Enanta Pharmaceuticals, Inc. Macrocyclic spiropyrrolidine derived antiviral agents
CA3224494A1 (en) 2021-07-09 2023-01-12 Koen Vandyck Anti-viral compounds
US12479854B2 (en) 2021-07-29 2025-11-25 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
WO2023043816A1 (en) 2021-09-17 2023-03-23 Aligos Therapeutics, Inc. Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections
US11858945B2 (en) 2021-11-12 2024-01-02 Enanta Pharmaceuticals, Inc. Alkyne-containing antiviral agents
US11919910B2 (en) 2021-11-12 2024-03-05 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11912714B2 (en) 2021-11-12 2024-02-27 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
US11993600B2 (en) 2021-12-08 2024-05-28 Enanta Pharmaceuticals, Inc. Saturated spirocyclics as antiviral agents
WO2023107417A1 (en) 2021-12-08 2023-06-15 Enanta Pharmaceuticals, Inc. Heterocyclic antiviral agents
CN114133350B (zh) * 2021-12-16 2023-05-23 浙江乐普药业股份有限公司 一种抗新冠药物Paxlovid中间体的制备方法
WO2023149981A1 (en) * 2022-02-07 2023-08-10 Purdue Research Foundation Compounds for the treatment of sars
US12145942B2 (en) 2022-04-05 2024-11-19 Enanta Pharmaceuticals, Inc. Spiropyrrolidine derived antiviral agents
CN114736151B (zh) * 2022-04-13 2023-04-21 湖南复瑞生物医药技术有限责任公司 一种帕罗韦德关键中间体制备方法及化合物的结构式
CN115160205B (zh) * 2022-07-08 2024-06-07 上海皓鸿生物医药科技有限公司 一种制备(s)-1-(叔丁氧羰基)-2,5-二氢-1h-吡咯-2-羧酸及盐的方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU177134B (en) * 1977-07-18 1981-07-28 Richter Gedeon Vegyeszet Process for preparing angiotensin ii analogues containing alpha-hydroxy-acid in position 1 with angiotensin ii antagonist activity
DE2936099A1 (de) * 1979-09-06 1981-04-02 Victor Dipl.- Chem. 8000 München Brantl Pharmakologisch aktive peptide
JPS5781447A (en) * 1980-11-11 1982-05-21 Toyo Jozo Co Ltd Human chorionic gonadotropic hormone c-terminal fragment
EP0124317B1 (en) * 1983-04-27 1990-04-11 Ici Americas Inc. Proline derivatives
ZA86746B (en) 1985-02-04 1986-09-24 Merrell Dow Pharma Novel peptidase inhibitors
US5496927A (en) * 1985-02-04 1996-03-05 Merrell Pharmaceuticals Inc. Peptidase inhibitors
BR8807310A (pt) 1987-11-18 1990-03-13 Chiron Corp Polinucleotidio,polinucleotidio recombinante,vetor recombinante,celula hospedeira,sistema de expressao recombinante,celula transformada,polipeptidio,hcv,preparacao de polipeptidio,polipeptidio de hcv,polipeptidio purificado,polipeptidio recombinante,polipeptidio de fusao,anticorpo monoclonal,preparacao purificada de anticorpos policlonais,particula,sonda de polinucleotidio,kit anticorpo para epetopo de hcv,metodo para producao de polipeptidio,metodo para deteccao de acidos nucleicos de hcv,imunoensaio para detectar antigeno de hcv,imunoensaio para detectar anticorpos dirigidos contra antigeno de hcv,vacina para tratamento de infeccao de hcv,celula,celula infectada com hcv,metodo para producao de anticorpos para hcv e metodo para isolar cdna derivado do genoma de um agente infeccioso nao identificado
ZA897515B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
ATE132182T1 (de) 1989-02-01 1996-01-15 Asahi Glass Co Ltd Azeotrope oder azeotropähnliche zusammensetzung auf der basis von chlorfluorkohlenwasserstoffen
US5162500A (en) * 1989-04-15 1992-11-10 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Poststatin and related compounds or salts thereof
US5359138A (en) * 1989-04-15 1994-10-25 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Poststatin and related compounds or salts thereof
DE69133617D1 (de) 1990-04-04 2009-07-23 Novartis Vaccines & Diagnostic Protease von Hepatitis C Virus
JP2804817B2 (ja) 1990-04-13 1998-09-30 財団法人微生物化学研究会 ３―アミノ―２―オキソ脂肪酸誘導体の製造法
JPH04149166A (ja) 1990-10-12 1992-05-22 Nippon Kayaku Co Ltd 新規ケト酸アミド誘導体
WO1992011850A2 (en) 1990-12-28 1992-07-23 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
FR2686086A1 (fr) * 1992-01-15 1993-07-16 Adir Nouveaux derives de peptides et de pseudopeptides therapeutiquement actifs dans la cascade de coagulation sanguine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
JP3439209B2 (ja) * 1992-01-31 2003-08-25 アボツト・ラボラトリーズ Ｈｃｖ蛋白のための哺乳動物発現システム
EP0650368A1 (en) 1992-06-24 1995-05-03 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity
US5514694A (en) * 1992-09-21 1996-05-07 Georgia Tech Research Corp Peptidyl ketoamides
US5414018A (en) * 1993-09-24 1995-05-09 G. D. Searle & Co. Alkylaminoalkyl-terminated sulfide/sulfonyl-containing propargyl amino-diol compounds for treatment of hypertension
US5843450A (en) * 1994-02-14 1998-12-01 Abbott Laboratories Hepatitis GB Virus synthetic peptides and uses thereof
IT1272179B (it) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
US6285380B1 (en) * 1994-08-02 2001-09-04 New York University Method and system for scripting interactive animated actors
RU2104284C1 (ru) * 1994-10-20 1998-02-10 Научно-исследовательский институт вирусологии им.Д.И.Ивановского РАМН Синтетические олигопептиды, специфически взаимодействующие с антителами к вирусу гепатита с, способы диагностики hcv-инфекции (варианты)
US5843752A (en) * 1995-05-12 1998-12-01 Schering Corporation Soluble active hepatitis C virus protease
US5919765A (en) 1995-06-07 1999-07-06 Cor Therapeutics, Inc. Inhibitors of factor XA
GB9517022D0 (en) 1995-08-19 1995-10-25 Glaxo Group Ltd Medicaments
US5763576A (en) * 1995-10-06 1998-06-09 Georgia Tech Research Corp. Tetrapeptide α-ketoamides
IL120310A (en) 1996-03-01 2002-02-10 Akzo Nobel Nv Serine protease inhibitors and pharmaceuticals containing them
US5633388A (en) * 1996-03-29 1997-05-27 Viropharma Incorporated Compounds, compositions and methods for treatment of hepatitis C
US5736576A (en) * 1996-06-04 1998-04-07 Octamer, Inc. Method of treating malignant tumors with thyroxine analogues having no significant hormonal activity
WO1998007734A1 (en) 1996-08-21 1998-02-26 Hybridon, Inc. Oligonucleotide prodrugs
IT1285158B1 (it) 1996-09-17 1998-06-03 Angeletti P Ist Richerche Bio Polipeptidi solubili con l'attivita' di serino-proteasi di ns3 del virus dell'epatite c, e procedimento per la loro preparazione e il
CN1238002A (zh) 1996-09-24 1999-12-08 普罗格特-甘布尔公司 含有蛋白水解酶、肽醛和硼酸源的液体洗涤剂
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
CZ298749B6 (cs) * 1996-10-18 2008-01-16 Vertex Pharmaceuticals Incorporated Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
JP2001508418A (ja) 1996-12-27 2001-06-26 ベーリンガー インゲルハイム（カナダ）リミテッド ヒトサイトメガロウイルスプロテアーゼのペプチドミメティックインヒビター
WO1998037180A2 (en) 1997-02-22 1998-08-27 Abbott Laboratories Hcv fusion protease and polynucleotide encoding same
DE69829381T2 (de) 1997-08-11 2006-04-13 Boehringer Ingelheim (Canada) Ltd., Laval Hepatitis c inhibitor peptide
EP1012180B1 (en) * 1997-08-11 2004-12-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
GB9809664D0 (en) 1998-05-06 1998-07-01 Hoffmann La Roche a-Ketoamide derivatives
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
US6576613B1 (en) * 1998-07-24 2003-06-10 Corvas International, Inc. Title inhibitors of urokinase
AR022061A1 (es) * 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
JP2000256396A (ja) 1999-03-03 2000-09-19 Dainippon Pharmaceut Co Ltd 複素環式化合物およびその中間体ならびにエラスターゼ阻害剤
UA74546C2 (en) * 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
WO2001040262A1 (en) * 1999-12-03 2001-06-07 Bristol-Myers Squibb Pharma Company Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
JP4806154B2 (ja) * 2000-04-03 2011-11-02 バーテックス ファーマシューティカルズ インコーポレイテッド セリンプロテアーゼ、特にｃ型肝炎ウイルスｎｓ３プロテアーゼのインヒビター
MXPA03000627A (es) * 2000-07-21 2004-07-30 Schering Corp Nuevos peptidos como inhibidores de proteasa serina-ns3 del virus de la hepatitis c.
AR029851A1 (es) * 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
US7244721B2 (en) 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m

Also Published As

Publication number Publication date
ECSP034438A (es) 2003-03-10
LU91910I2 (fr) 2012-02-02
SK752003A3 (en) 2003-08-05
US7012066B2 (en) 2006-03-14
CA2410662A1 (en) 2002-01-31
TWI324611B (en) 2010-05-11
IL153670A0 (en) 2003-07-06
JP4298289B2 (ja) 2009-07-15
DE122012000004I1 (de) 2012-04-26
USRE43298E1 (en) 2012-04-03
PL206255B1 (pl) 2010-07-30
CN102206247A (zh) 2011-10-05
NO2013003I1 (no) 2013-03-04
RU2008126266A (ru) 2010-01-10
HK1058047A1 (en) 2004-04-30
DE60141608D1 (de) 2010-04-29
NZ523782A (en) 2005-10-28
SI1385870T1 (sl) 2010-08-31
US20040254117A9 (en) 2004-12-16
AR033985A1 (es) 2004-01-21
NO20030272D0 (no) 2003-01-20
MY139078A (en) 2009-08-28
AR069373A2 (es) 2010-01-20
US20030216325A1 (en) 2003-11-20
AU7698801A (en) 2002-02-05
NO20030272L (no) 2003-03-21
JP2009051860A (ja) 2009-03-12
BR0112540A (pt) 2003-06-24
PT1385870E (pt) 2010-06-07
PL366063A1 (en) 2005-01-24
KR20030025277A (ko) 2003-03-28
CY1112267T1 (el) 2015-12-09
MY143322A (en) 2011-04-15
EP1385870A2 (en) 2004-02-04
ES2341534T3 (es) 2010-06-22
RU2355700C9 (ru) 2010-03-20
DK1385870T3 (da) 2010-07-05
AU2001276988B2 (en) 2007-01-25
ZA200210312B (en) 2004-03-29
ATE461207T1 (de) 2010-04-15
CN102372764A (zh) 2012-03-14
SK288064B6 (sk) 2013-04-03
CN1498224A (zh) 2004-05-19
WO2002008244A2 (en) 2002-01-31
HUP0401730A2 (hu) 2004-12-28
US20060205672A1 (en) 2006-09-14
CZ2003151A3 (cs) 2003-05-14
CY2011020I2 (el) 2016-12-14
CN102206247B (zh) 2013-03-27
KR100939155B1 (ko) 2010-01-28
JP5775505B2 (ja) 2015-09-09
CY2011020I1 (el) 2016-12-14
IL153670A (en) 2012-06-28
JP2013032389A (ja) 2013-02-14
NO332329B1 (no) 2012-09-03
MXPA03000627A (es) 2004-07-30
WO2002008244A3 (en) 2003-06-19
RU2355700C2 (ru) 2009-05-20
CZ303213B6 (cs) 2012-05-23
HUP0401730A3 (en) 2012-09-28
JP2004504404A (ja) 2004-02-12
CA2410662C (en) 2012-09-18
NO2013003I2 (no) 2017-01-16
US20110117057A1 (en) 2011-05-19
KR20090030330A (ko) 2009-03-24
EP1385870B1 (en) 2010-03-17
KR100904788B1 (ko) 2009-06-25

Similar Documents

Publication Publication Date Title
SI1385870T1 (sl) Peptidi kot NS3-serin proteazni inhibitorji virusa hepatitisa C
IL153669A0 (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
AU2001280640A1 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
AU2001277967A1 (en) Peptides as ns3-serine protease inhibitors of hepatitis c virus
IL155842A0 (en) Diaryl peptides as ns3-serine protease inhibitors of hepatitis c virus
AU2002230763A8 (en) Inhibitors of hepatitis c virus ns3 protease
IL162815A0 (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
AU2001245356A1 (en) Inhibitors of hepatitis c virus ns3 protease
GB0107924D0 (en) Inhibitor of hepatitis C virus NS3 protease
AU2055301A (en) Alpha-ketoamide inhibitors of hepatitis c virus ns3 protease
AU2001282922A1 (en) Novel imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus
AU6371900A (en) Lactam inhibitors of hepatitis c virus ns3 protease
AU5788800A (en) Peptide boronic acid inhibitors of hepatitis c virus protease
IL151934A0 (en) Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties
AU2002230764A1 (en) Imidazolidinones and their related derivatives as hepatitis c virus ns3 protease inhibitors
HUP0000152A2 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
IL151935A0 (en) Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising alkyl and aryl alanine p2 moieties
SI0932617T1 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease
EP1141255A4 (en) MODIFIED FORMS OF HEPATITIS C VIRUS NS3 PROTEASE
HK1050688A (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
AU2002350322A1 (en) Inhibitors of hepatitis c virus protease
AU2002308200A1 (en) Peptides and their use as inhibitors of hepatitis c virus ns3 protease
HK1090930A (en) Depeptidized inhibitors of hepatitis c virus ns3 protease
HK1088339A (en) Novel peptidomimetic ns3-serine protease inhibitors of hepatitis c virus

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: DENDREON CORPORATION, US

Free format text: FORMER OWNER(S): SCHERING CORP., US; CORVAS INTERNATIONAL, INC., US; DENDREON SAN DIEGO LLC, US; SCHERING CORP., US

Owner name: MERCK SHARP & DOHME CORP., US

Free format text: FORMER OWNER(S): SCHERING CORP., US; CORVAS INTERNATIONAL, INC., US; DENDREON SAN DIEGO LLC, US; SCHERING CORP., US

AA1S Information on application for a supplementary protection certificate

Free format text: PRODUCT NAME: BOCEPREVIR OR AN ENANTIOMER, STEREOISOMER, ROTAMER, TAUTOMER OR RACEMATE OF SAID COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE OF SAID COMPOUND; REG. NO/DATE: EU/1/11/704 20110718

Spc suppl protection certif: S1500017

Filing date: 20150330

Expiry date: 20210719

AA1S Information on application for a supplementary protection certificate

Free format text: PRODUCT NAME: BOCEPREVIR OR AN ENANTIOMER, STEREOISOMER, ROTAMER, TAUTOMER OR RACEMATE OF SAID COMPOUND OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE OF SAID COMPOUND; REGISTRATION NO/DATE: EU/1/11/704 20110720

Spc suppl protection certif: S1500044

Filing date: 20150902

Expiry date: 20210719

MM4A Lapse of definitive patent protection due to non-payment of fees